Abstract: Objective：Observe the clinical efficacy of the high accuracy continuous circulation intraperitoneal hyperthermic chemotherapy （IPHC） and intravenous chemotherapy for ovarian cancer. Methods：50 patients of The People′s Hospital of Zhengzhou University with satisfied ovarian cancer reductive surgery were divided into two groups：IPHC group, 28 patients with high accuracy continuous circulation intraperitoneal hyperthermic chemotherapy and intravenous chemotherapy;Control group, 22 patients with ″paclitaxel liposome 135 mg/m2 + oxaliplatin 135 mg/m2 ″（PT） intravenous chemotherapy，observed clinical treatment effect of two groups patients. Results：Compared the percentage of nomal CA125 of two groups patients after 1 month, 3 months, the difference was statistically significant （all P＜0.05）. Two group patients one month, three months ascites treatment efficiency difference was statistically significant（P＜0.05）. Compared the grade Ⅱ side effect of chemotherapy，IPHC group was lower than control group （χ2=7.417，P=0.006）；and IPHC group′s improment rate of life quality was higher than control group′s （χ2=5.936，P=0.015）. Conclusions：High accuracy continuous circulation intraperitoneal hyperthermic chemotherapy and intravenous chemotherapy can improve the clinical efficacy of ovarian cancer，control of malignant ascites of ovarian cancer patients effectively，reduce side effects of chemotherapy and improve quality of life.

Key words: Ovarian neoplasms, Chemotherapy, cancer, regional perfusion, Intraperitoneal hyperthermic chemotherapy